Author(s): LechMaranda E, Korycka A, Robak T
Abstract Share this page
Abstract More recently, three novel purine nucleoside analogs, including clofarabine, nelarabine and immucillin H, have been introduced into clinical trials. These agents have different metabolic properties, novel mechanism of action, and are undergoing phase I-II clinical studies for the treatment of hematopoietic malignancies. Pharmacology and anticancer activity of PNA are the subjects of this review.
This article was published in Mini Rev Med Chem
and referenced in Medicinal Chemistry